If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 82.50
Bid: 80.00
Ask: 85.00
Change: 0.00 (0.00%)
Spread: 5.00 (6.25%)
Open: 82.50
High: 82.50
Low: 82.50
Prev. Close: 82.50
FDBK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Bleepa to join DIT’s first virtual event to India

4 Dec 2020 07:00

RNS Number : 5239H
Feedback PLC
04 December 2020
 

Reach

 

Feedback plc

 

Bleepa selected for Department for International Trade India Healthcare Virtual Mission

 

· The India Healthcare Virtual Mission - 8-10 December

· India's healthcare market projected to grow to $372 billion by 2022

· Event enables engagement with key stakeholders and influencers in India's Healthcare industry

 

London, 4 December 2020: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, today announces that Bleepa has been selected by Healthcare UK, part of the Department for International Trade ("DIT"), to join a virtual healthcare mission to India, 8-10 December 2020.

 

DIT - India Healthcare Virtual Mission

 

This is the DIT's first virtual event to India, building on the success of trade delegations visiting India over the last four years. Leading British healthcare innovators in artificial intelligence in healthcare, digital health, smart diagnostics and home-care technology, for both the Covid and post-Covid world, are selected to join this mission, led by the Chairman of NHS England, Lord David Prior.

Innovation in healthcare delivery is a key priority for healthcare providers in India, as India's healthcare market is projected to grow to USD 372bn by 20221. The event offers the chance to interact with key stakeholders and influencers from the Indian healthcare industry, including high-profile speakers from reputed organisations on key issues/opportunities in the industry from both UK and India. Companies joining the mission will receive dedicated support from the DIT network.

 

Dr Tom Oakley, CEO of Feedback, commented:

 

"There are a number of potential opportunities for Bleepa within the large and growing Indian healthcare market such as with the newly announced National Digital Health Mission, which targets giving every Indian citizen a unique health ID and digitized health records.

 

"Bleepa has the ability to support the hub and spoke hospital system in India. With a population of 1.38 billion people, access to centres of excellence in the four major cities is not possible for all, with both capacity and funding limiting access to top tier treatment. We believe that Bleepa can provide the vital digital link between these centres of excellence and regional or even mobile care units, enabling millions more patients to receive the high standards of care targeted in the National Digital Health Mission.

 

"We believe that Bleepa's digital modular capabilities as a CE marked communications platform would make Bleepa an attractive option for the Indian market. We look forward to scoping the opportunities available with the support of Healthcare UK and DIT."

 

1. https://www.events.great.gov.uk/ehome/index.php?eventid=200212218&

 

-Ends-

 

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Lindsay Melvin, CFO

+44 (0)1954 718072

IR@fbk.com

Allenby Capital Limited (Nominated Adviser)

David Worlidge / Asha Chotai

+44 (0)20 3328 5656

Walbrook PR Ltd

Tel: 020 7933 8780 or feedbackplc@walbrookpr.com

Paul McManus/Nick Rome/Nicholas Johnson

07980 541 893 or 07748 325 236 or 07884 664 686

Notes to Editors

 

Feedback plc (AIM: FDBK) is a medical imaging technology business. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go.

 

Its highly scalable Software as a Service ("SaaS") based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care facilitators. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of diagnosis.

 

About Department for International Trade

 

The Department for International Trade (DIT) helps businesses export and grow into global markets. We also help overseas companies locate and grow in the UK. Our services are provided in over 100 markets throughout the world. We are passionate about what we do. That's why we constantly review our services in light of customer feedback and the impact they offer, which means they'll vary from time to time.

 

https://www.gov.uk/government/organisations/department-for-international-trade/about-our-services

 

About RNS Reach announcements

This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUORWRRVUURAA
Date   Source Headline
25th Mar 20247:00 amRNSNew tuberculosis partnership in India
21st Mar 20247:00 amRNSFurther CDC Pilot Programme Secured
23rd Feb 202411:03 amRNSHolding(s) in Company
21st Feb 20247:00 amRNSHalf-year Report
21st Feb 20247:00 amRNSMedical Imaging Partnership Pilot Agreement
6th Feb 20247:00 amRNSNotice of Results & Investor Presentation
19th Dec 20237:01 amRNSHalf Year Trading Update
19th Dec 20237:00 amRNSAward of Pilot Funding
26th Oct 20232:24 pmRNSResult of AGM
25th Oct 20235:53 pmRNSDirector Dealing
27th Sep 202312:15 pmRNSNotice of AGM
12th Sep 20237:00 amRNSFinal Results
5th Sep 20237:00 amRNSNotice of Results & Investor Presentation
19th Jun 20237:00 amRNSYear End Trading Update
4th Apr 20237:00 amRNSBleepa-CareLocker contract extension with QVH
7th Feb 20237:00 amRNSHalf-year Report
3rd Feb 20233:56 pmRNSHolding(s) in Company
11th Jan 20237:00 amRNSNotice of Results, Analyst & Investor Presentation
22nd Dec 202212:08 pmRNSDirector/PDMR Shareholding: Correction
22nd Dec 20227:00 amRNSDirector/PDMR Shareholding
19th Dec 20227:00 amRNSHalf Year Trading Update
1st Nov 20223:36 pmRNSTotal Voting Rights
13th Oct 20222:55 pmRNSResult of AGM & Proposed Share Consolidation
29th Sep 20223:46 pmRNSHolding(s) in Company
20th Sep 20223:26 pmRNSNotice of AGM & Proposed Share Consolidation
20th Sep 20227:00 amRNSFinal Results
13th Sep 20227:00 amRNSNotice of Results & Investor Presentation
6th Sep 20227:00 amRNS12 month contract for Sussex CDC pilot extension
19th Jul 20227:00 amRNSContract Update
16th Jun 20227:00 amRNSYear End Trading Update
1st Jun 20227:00 amRNSTrading Update & Director Appointment
12th May 202212:44 pmRNSChange of Registered Office
12th Apr 20227:00 amRNSBleepa wins two NHS Contract Awards
31st Mar 20227:00 amRNSBleepa TB Screening Pilot Now Live in Odisha
23rd Feb 20227:00 amRNSGrant of Options and PDMR dealing
10th Feb 20227:00 amRNSInterim Results
31st Jan 20227:00 amRNSNotice of Results
13th Dec 20217:00 amRNSPartnership with Amazon Web Services
6th Dec 20213:06 pmRNSHolding(s) in Company
2nd Dec 202110:20 amRNSDirector/PDMR Shareholding
2nd Dec 20219:54 amRNSHolding(s) in Company
1st Dec 20214:27 pmRNSHolding(s) in Company
1st Dec 20213:09 pmRNSHolding(s) in Company
30th Nov 20214:05 pmRNSHolding(s) in Company
29th Nov 20211:36 pmRNSDirector Appointment
29th Nov 20211:35 pmRNSResults of AGM, Open Offer, Issue of Equity & TVR
18th Nov 202112:15 pmRNSHolding(s) in Company
16th Nov 20214:35 pmRNSPrice Monitoring Extension
2nd Nov 20211:52 pmRNSResult of Placing
2nd Nov 20217:01 amRNSProposed Placing and Open Offer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.